Thin
1 / 1
This is the main indication for which Semax has been approved in Russia. It is used in the acute and recovery phases to limit the infarct area, protect dying neurons, and promote functional recovery.
Used to treat vascular and post-traumatic cognitive impairment, it can improve memory, attention, and psychological performance.
As an adjunct therapy, it is especially effective for depressive states associated with burnout and cognitive decline.
Its potential for use in Alzheimer's and Parkinson's diseases is being investigated, primarily based on its neurotrophic and protective effects.
Used to treat optic nerve damage and atrophy caused by diseases such as glaucoma.
In some regions (for non-medical purposes), it is used as a "nootropic" to enhance learning, memory, and mental concentration under stress.
Semax represents a promising class of neurotrophic and neuroprotective agents. Originating as a relatively niche Russian drug, it is gradually gaining attention from the global neuroscience community. Its future development will heavily depend on successful clinical studies conducted under international standards and a deeper understanding of its powerful but complex mechanism of action. If these challenges are overcome, Semax holds the promise of becoming an important tool for treating a variety of brain diseases.
Semax is a synthetic peptide derived from an ACTH fragment, developed in Russia in the 1980s by the Institute of Molecular Genetics. It eliminates hormonal activity while enhancing beneficial effects on the central nervous system.
Its primary approved indication in Russia is for ischemic stroke, applied during both acute and recovery phases to reduce the infarct zone, protect neurons, and enhance functional recovery.
Semax is applied or studied for cognitive impairment, anxiety and depressive disorders, optic neuropathy (e.g., from glaucoma), and neurodegenerative diseases like Alzheimer's and Parkinson's diseases.
Yes, in several regions Semax is used non-medically as a cognitive enhancer or nootropic to support memory, learning capabilities, and focus during high-stress conditions.
Researchers have worked on novel analogues like Selank (frequently used for anxiety) and Adamamax (engineered as a more stable version of Semax) for extended duration and potency.
It requires large-scale randomized, double-blind, placebo-controlled clinical trials matching FDA/EMA guidelines, complete clarification of molecular pathways, and increased market awareness.
